Eli Lilly: A Strong Buy Amidst Obesity Treatment Market …
WEB23 hours ago · In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,150.00. Alec Stranahan ...
Lilly expands manufacturing footprint in Ireland with $1.8 billion ...
WEBINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, May 24, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company's total investment in this site from $3.7 billion to $9 billion.
All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
Eli Lilly (LLY) earnings Q2 2024 - CNBC
WEBAug 8, 2024 · That compares with a profit of $1.76 billion, or $1.95 a share, a year earlier. Excluding one-time items associated with the value of intangible assets and other adjustments, Eli Lilly posted ...
Eli Lilly Trial Finds Alzheimer’s Drug Can Slow Progress of Disease
WEBMay 3, 2023 · The F.D.A. approved a new drug for early Alzheimer’s, the latest in a novel class of treatments that has been greeted with hope, disappointment and skepticism. A study suggests that genetics...
Alzheimer's drug donanemab shows positive results, Eli Lilly ... - CNBC
WEBJul 17, 2023 · Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New ...
WEB1 day ago · Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. ... Of course, any negative news regarding GLP-1 side effects or adverse FDA decisions could weigh on this high-P/E ...
Skip to content